Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.

Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.

The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.

The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.

Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.

The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.

RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.

RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.

Nanotechnology offers improved options for the diagnosis and treatment of cancer.

In a new publication, RIVM indicates scientific challenges in the use of the EU definition for nanomaterial in legislation.